$59.58
5.12% yesterday
Nasdaq, Nov 17, 10:00 pm CET
ISIN
US6402681083
Symbol
NKTR

Nektar Therapeutics Stock price

$59.58
+1.81 3.13% 1M
+49.16 471.51% 6M
+45.63 327.10% YTD
+44.13 285.63% 1Y
+8.13 15.80% 3Y
-203.82 77.38% 5Y
-155.97 72.36% 10Y
-180.87 75.22% 20Y
Nasdaq, Closing price Mon, Nov 17 2025
+2.90 5.12%
ISIN
US6402681083
Symbol
NKTR
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$941.7m
Net debt
positive
Cash
$270.2m
Shares outstanding
19.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
19.4 | 28.1
EV/Sales
15.0 | 21.9
EV/FCF
negative
P/B
14.2
Financial Health
Equity Ratio
20.0%
Return on Equity
-195.9%
ROCE
-58.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$62.6m | $43.1m
EBITDA
$-135.2m | $-143.8m
EBIT
$-136.4m | $-164.2m
Net Income
$-120.7m | $-230.9m
Free Cash Flow
$-190.4m
Growth (TTM | estimate)
Revenue
-32.8% | -56.2%
EBITDA
-3.8% | -14.6%
EBIT
-0.3% | -26.4%
Net Income
28.3% | -94.1%
Free Cash Flow
-7.1%
Margin (TTM | estimate)
Gross
87.3%
EBITDA
-216.0% | -333.9%
EBIT
-217.8%
Net
-192.9% | -536.0%
Free Cash Flow
-304.1%
More
EPS
$-6.4
FCF per Share
$-9.7
Short interest
7.4%
Employees
61
Rev per Employee
$1.6m
Show more

Is Nektar Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Nektar Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Nektar Therapeutics forecast:

11x Buy
79%
2x Hold
14%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Nektar Therapeutics forecast:

Buy
79%
Hold
14%
Sell
7%

Financial data from Nektar Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
63 63
33% 33%
100%
- Direct Costs 7.98 7.98
73% 73%
13%
55 55
14% 14%
87%
- Selling and Administrative Expenses 75 75
3% 3%
119%
- Research and Development Expense 116 116
5% 5%
186%
-135 -135
4% 4%
-216%
- Depreciation and Amortization 1.17 1.17
79% 79%
2%
EBIT (Operating Income) EBIT -136 -136
0% 0%
-218%
Net Profit -121 -121
28% 28%
-193%

In millions USD.

Don't miss a Thing! We will send you all news about Nektar Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nektar Therapeutics Stock News

Positive
Seeking Alpha
6 days ago
Nektar Therapeutics (NKTR) develops novel immunomodulatory drugs targeting autoimmune diseases and oncology, leveraging its expertise in immune system regulation. Recent Phase 2 results for Atopic Dermatitis met endpoints, validating NKTR's approach and boosting confidence in its platform's clinical potential. NKTR's pipeline includes rezpegaldesleukin for other indications, and NKTR-255 for ca...
Positive
Seeking Alpha
6 days ago
Nektar Therapeutics has pivoted from oncology to focus on autoimmune and inflammatory diseases, with Rezpegaldesleukin (Rezpeg) as its lead asset. NKTR's value now centers on Treg biology, advancing Rezpeg and NKTR-0165, and leveraging legacy oncology partnerships for monetization. Key catalysts are upcoming Q1 2026 readouts: Phase 2b alopecia areata data and 36-week atopic dermatitis data for ...
Neutral
PRNewsWire
9 days ago
Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Extended dosing with rezpegaldesleukin q2w supports 24-week induction period for planned Phase 3 studies with improvement across major efficacy endpoints from Week 16 to 24, including EASI-75, EASI-90, and vIG...
More Nektar Therapeutics News

Company Profile

Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The firm focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.

Head office United States
CEO Howard Robin
Employees 61
Founded 1990
Website www.nektar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today